Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
rTM001 trial: thrombomodulin alfa with conditioning regimens in allogeneic stem cell transplantation for elderly hematologic malignancies
jRCTs031190075Recruiting
- Start
- Aug 2019
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Open-label, single-arm trial of thrombomodulin alfa in hematopoietic malignancies, leukemia, lymphoma and 1 more. Primary endpoint: Bleeding episodes during conditioning with thrombomodulin alfa. Started Aug 2019; status: recruiting.
02
Drugs
thrombomodulin alfa
03
Conditions
hematopoietic malignanciesleukemialymphomamyelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on jRCTs031190075.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031190075.